AstraZeneca

Veeva Systems announces Veeva Site Connect, enhancing sponsor-site collaboration with new capabilities and a streamlined experience, reducing trial time and cost. Seven top 20 biopharmas have adopted the platform for simplified trial execution.

The article presents various studies on antibody drug conjugates, including datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), in different cancer types such as endometrial, ovarian, breast, lung, and gastric cancers. It also covers studies on immuno-oncology treatments like durvalumab and neoadjuvant strategies, as well as initial results from first-in-human studies of new antibody-drug conjugates like AZD8205 and AZD5335. Additionally, it discusses the role of circulating tumor DNA (ctDNA) dynamics in treatment responses and long-term survival outcomes in various cancer settings.

Lupus disproportionately affects racial and ethnic minorities, yet they're underrepresented in clinical trials. LuCIN aims to bridge this gap by enhancing diversity through investigator and research staff engagement, addressing barriers like socioeconomic factors and mistrust, and promoting culturally appropriate communication and education.

Health disparities in lupus among racial and ethnic minorities are addressed through research identifying 33 solutions in categories like Financial Safety Net and Patient Education. High-priority solutions include personalized care and Medicaid expansion to improve healthcare equity and outcomes.

Deepak Bhatt, a prominent cardiologist, discussed common pitfalls in interpreting clinical trial data at the ESC Congress 2024. His work, cited over 275,000 times, focuses on pivotal trials like REDUCE-IT and SCORED. Bhatt highlighted the 17-year lag between scientific discovery and its adoption into clinical practice.

Nurix Therapeutics' NX-1607, an oral CBL-B inhibitor, is in clinical trials to enhance T cell activation, addressing limitations of immune checkpoint inhibitors. Initial results presented at ACS Spring 2024.

The global biotechnology market, valued at USD 1.55 trillion in 2024, is projected to reach USD 4.61 trillion by 2034, growing at a CAGR of 11.5%. North America led with a 37.79% revenue share in 2023, driven by strong R&D and healthcare spending. Asia-Pacific is expected to grow at over 12.4%, supported by healthcare improvements and government regulations. Key growth factors include technological advancements, rising disease prevalence, and increased R&D investments. Bio-pharmacy dominates the market, with bio-informatics expected to grow rapidly. Tissue engineering and regeneration lead in technology, with chromatography growing fastest.

FDA approved Johnson & Johnson's Rybrevant with Lazcluze for untreated, advanced non-small cell lung cancer with specific EGFR mutations. This chemotherapy-free regimen showed a 30% lower risk of cancer progression or death compared to AstraZeneca's Tagrisso, despite higher side effects. Patients require prophylactic anticoagulation due to safety concerns.

Imfinzi approved in the US for treating resectable non-small cell lung cancer before and after surgery, based on the AEGEAN trial showing a 32% reduction in risk of recurrence.

AstraZeneca's Imfinzi (durvalumab) sBLA for LS-SCLC treatment post-cCRT accepted by FDA with Priority Review, based on ADRIATIC Phase III trial showing 27% reduced death risk. FDA decision expected Q4 2024. Imfinzi also granted Breakthrough Therapy Designation, aiming to address urgent need for new LS-SCLC treatments.